STARTUP PROFILE

Nyxoah

COUNTRY
Belgium
FOUNDED
2009
CATEGORY
Neuromodulation
Developing an implantable neuromodulation system to treat obstructive sleep apnea by stimulating the hypoglossal nerve.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Public
MODALITY
Nerve stimulator
FORM FACTOR
Implant
INTERFACE DEPTH
Implantable
INDICATION
Sleep
TARGET USER
Patients
REGULATORY STAGE
FDA approved (PMA)
Nyxoah is an established public neuromodulation company in sleep apnea, using hypoglossal nerve stimulation to compete with other implantable airway therapies. Its scale and maturity place it well beyond startup stage, even if it sits somewhat outside core neurotechnology themes.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
12
NVIDIA and OpenAI invest in neurotech
13 October – 27 October 2026

Nyxoah presented 12-month ACCCESS data, showing a 77.2% responder rate for its Genio implant in sleep apnea patients with complete concentric collapse. The company also filed with the FDA to expand its US label. Days later, it lowered its 2026 revenue guidance to €33M-€35M, citing a slower-than-expected US rollout.

#
9
BCI Shows its Value
1 September – 15 September 2026

Nyxoah reported that its ACCCESS pivotal study met its primary safety and efficacy endpoints in patients with complete concentric collapse, a form of obstructive sleep apnea excluded from competing nerve-stimulation therapies. Across 47 patients, Genio achieved a 77.2% responder rate on the apnea-hypopnea index, with no device-related serious adverse events. The leadless, battery-free implant stimulates both sides of the hypoglossal nerve to keep the airway open during sleep. Nyxoah is preparing an FDA submission to expand Genio's US indication and has separately begun its BREATHE post-approval study.

Articles featuring
Nyxoah